Psoriasis and its comorbidities

Journal of Drugs in Dermatology

Volumn 11, Issue 5, 2012, Pages

  Onumah, Neh ^a   Kircik, Leon H ^b,c  

^a Graves Dermacare Center PC   (United States)

^b MOUNT SINAI MEDICAL CENTER   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AMINOTRANSFERASE; C REACTIVE PROTEIN; CYCLOSPORIN; ETANERCEPT; GAMMA INTERFERON; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INFLIXIMAB; INTERLEUKIN 12; INTERLEUKIN 6; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA;

ABDOMINAL OBESITY; AMINOTRANSFERASE BLOOD LEVEL; ANXIETY; ARTICLE; BRAIN ATHEROSCLEROSIS; CARDIOMETABOLIC RISK; CAROTID ATHEROSCLEROSIS; COHORT ANALYSIS; COMORBIDITY; CORONARY ARTERY ATHEROSCLEROSIS; CROHN DISEASE; CROSS-SECTIONAL STUDY; CUTANEOUS T CELL LYMPHOMA; DEPRESSION; DISEASE ASSOCIATION; DISEASE SEVERITY; ENTHESITIS; HEART INFARCTION; HODGKIN DISEASE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; IMMUNOPATHOLOGY; INSULIN RESISTANCE; LIPOPROTEIN BLOOD LEVEL; LYMPHOPROLIFERATIVE DISEASE; MEDITATION; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; PREVALENCE; PROTEIN BLOOD LEVEL; PSORIASIS; PSORIATIC ARTHRITIS; QUALITY OF LIFE; SKIN INFLAMMATION; SLEEP DISORDER; SPONDYLOARTHROPATHY; STROKE; ULCERATIVE COLITIS;

ANIMALS; ARTHRITIS; CARDIOVASCULAR DISEASES; COMORBIDITY; DIABETES MELLITUS; HUMANS; INFLAMMATION MEDIATORS; METABOLIC SYNDROME X; PSORIASIS;

EID: 84860897190     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Abuabara K, Azfar RS, Shin DB, et al. Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the United Kingdom. Br J Dermatol. 2010;163:586-592.
2. Girolomoni G, Gisondi P. Psoriasis and systemic inflammation: underdiagnosed enthesopathy. J Eur Acad Dermatol Vener. 2009;23(suppl 1):3S-8S.
3. Taylor W, Gladman D, Helliwell P, the CASPAR Study Group. Classification criteria for psoriatic arthritis. Development of new criteria from a large international study. Arthritis Rheum. 2006;54:2665-2673. (Pubitemid 44205029)
4. Vena GA, Vestita M, Cassano N. Can early treatment with biologicals modify the natural history of comorbidities? Dermatol Therapy. 2010;181-193.
5. Gladman DD, Mease PJ, Choy EH, et al. Risk factors for radiographic progression in psoriatic arthritis: subanalysis of the randomized control trial ADEPT. Arthritis Res Ther. 2010;12:R113.
6. Menter A, Korman N, Elmets C Feldman S Gelfand J, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis section 6:case-based presentations and evidence-based conclusions. J Am Acad Deratol. 2011;65:137-174.
7. Shbeeb M, Uramoto KM, Gibson LE, O'Fallon Wm, Gabriel SE. The epidemiology of psoriatic arthritis in Olmsted County, Minnesota, USA, 1982-1991. J Rheumatol. 2000;27:1247-1250. (Pubitemid 30262512)
8. Gottlieb AB, Mease PJ, Mark Jackson J, Eisen D, et al. Clinical characteristics of psoriatic arthritis and psoriasis in dermatologists' offices. J Dermatol Treat. 2006;17:279-287. (Pubitemid 44595016)
9. De Filippis LG, Caliri A Lo Gullo R, et al. Ultrasonography in the early diagnosis of psoriasis-associated enthesopathy. Int J Tissue React. 2005;27:159-162. (Pubitemid 43056215)
10. Kremers HM, McEvoy MT, Dann FJ, Gabriel SE. Heart disease in psoriasis. J Am Acad Dermatol. 2007;57:347-354. (Pubitemid 47048862)
11. Mallbris L, Akre O, Granath F, Yin L, Lindelof B, Ekbom A, et al. Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur J Epidemiol. 2004;19:225-230. (Pubitemid 38461682)
12. Gelfand JM, Neimann, AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006;296:1735-1741. (Pubitemid 44547793)
13. Boehncke WH, Boehncke S, Tobin AM, Kirby B. The 'psoriatic march' a concept of how severe psoriasis may drive cardiovascular comorbidity. Exp Dermatol. 2011;20:303-307.
14. Boehncke WH. Epidemiology and potential pathomechanisms of cardiovascular comorbididites in psoriasis: A report form the GRAPPA 2010 annual meeting. J Rheum. 2012;39(2):441-444.
15. BoehnckeWH, Boehncke S. Research in practice: the systemic aspects of psoriasis. J Dtsch Dermatol Ges. 2008;6(8):622-625.
16. Gottlieb A, Chao C, Dann F. Psoriasis comorbidities. J Dermatol Treatment. 2008;19:5-21. (Pubitemid 351252710)
17. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001;24:683-689. (Pubitemid 32893993)
18. Sommer DM, Jenisch S, Suchan M, Christophers E, Weichenthal M. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res. 2006;298:321-328.
19. Love TJ, Qureshi AA, Karlson EW, Gelfand JM, Choi HK. Prevalence of the methabolic syndrome in psoriasis. Arch Dermatol. 2011;147(4):419-424.
20. Gisondi P, Del Giglo M, Cozzi A, Girolomoni G. Psoriasis, the liver, and the gastrointestinal tract. Dermatol Ther. 2010;23:155-159.
21. Di Cesare A, Di Meglio P, Nestly FO. The Il-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol. 2009;129:1339-1350.
22. Wolf N Quaranta M, Prescott NJ, et al. Psoriasis is associated with pleiotropic susceptibility loci identified in type II diabetes and Crohn disease. J Med Genet. 2008;45:114-116.
23. Lee FI, Bellary SV, Francis C. Increased occurrence of psoriasis in patients with Crohn's disease and their relatives. Am J Gastroenterol. 1990;85:962-963. (Pubitemid 20235791)
24. Eposito M, Saraceno R, Giunta A, Maccarone M, Chimenti S. An Italian study on psoriasis and depression. Dermatology. 2006;212:123-127. (Pubitemid 43260727)
25. Gupta MA, Gupta AK. Depression and suicidal ideation in dermatology patients with acne, alopecia areata, atopic dermatitis, and psoriasis. Br J Dermatol. 1998;139:846-850. (Pubitemid 28520293)
26. Sharma N, Koranne, RV, Singh RK. Psychiatric morbidity in psoriasis and vitiligo: A comparative study. J Dermatol. 2001;28:419-423. (Pubitemid 32862057)
27. Akay A, Pekcanlar A, Bozdag KE, Altintas L, Karaman A. Assessment of depression in subjects with psoriais vulgaris and lichen planus. J Eur Acad Dermatol Venereol. 2002;16:347-352. (Pubitemid 34918815)
28. Gulliver W. Long-term prognosis in patients with psoriasis. Bri J Dermatol. 2008;159(suppl 2):2-9.
29. Tyring S, Gottlieb A, Papp K, et al. Etanercept and clinical outcomes fatigue, and depression in psoriasis: Double-blind placebo-controlled randomized phase III trial. Lancet. 2006;367:29-35. (Pubitemid 43038667)
30. Kiortsis DN, Mavridis AK, Vasakos S, Nikas SN, Drosos AA. Effects of infliximab treatment on insulin resistance in patients with rheumatoid arthritis and ankylosin spondylitis. Ann Rheum Dis. 2005;64:765-766. (Pubitemid 40559306)
31. Ucak S, Ekmekci TR, Basat O, Koslu A, Altuntas Y. Comparison of various insulin sensitivity indices in psoriatic patients and their relationship with type of psoriasis. J Eur Acad Dermatol Venereol. 2006;20:517-522.
32. Patarca R, Klimas NG, Lugtendorf S, Antoni M, Fletcher MA. Dysregulated expression of tumor necrosis factor in chronic fatigue syndrome: Interrelations with cellular sources and patterns of soluble immune mediator expression. Clin Infect Dis. 1994;18(suppl 1):147S-153S.
33. Gelfand JM, Shin D, et al. The risk of lymphoma in patients with psoriasis. J Invest Dermatol. 2006;126:2194-2201. (Pubitemid 44413165)